Growth hormone therapy for children and adolescents with prader-willi syndrome is associated with improved body composition and metabolic status in adulthood

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Coupaye, Muriel ^{a,b,c,d,f,g,h,n}   Lorenzini, Françoise ^d,e   Lloret Linares, Célia ^a,b,c,d   Molinas, Catherine ^d   Pinto, Graziella ^d,i   Diene, Gwenaëlle ^d,f,g   Mimoun, Emmanuelle ^d,f,g   Ve Demeer, Geneviè ^d,j   Labrousse, Florence ^d,e   Jauregi, Joseba ^d,i,l,m   Laurier, Virginie ^d,i   Basdevant, Arnaud ^a,b,c,d,l,m   Polak, Michel ^d,i,l,m   Thuilleaux, Denise ^d,j,k   Tauber, Maïthé ^d,f,g,h   Poitou, Christine ^a,b,c,d,l,m  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre de Recherche en Nutrition Humaine Ile de France   (France)

^c Institute of Cardiometabolism and Nutrition   (France)

^d French Reference Centre for Prader Willi Syndrome   (France)

^e CHU RANGUEIL   (France)

^f HÔPITAL DES ENFANTS   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h France   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^l INSERM   (France)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ CNRS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; SULFONYLUREA;

ADOLESCENCE; ADULT; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILDHOOD; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; EARLY CHILDHOOD INTERVENTION; ENERGY EXPENDITURE; FAT MASS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE INDEX; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULINEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RESTING METABOLIC RATE; TREATMENT DURATION;

ADOLESCENT; ADULT; BASAL METABOLISM; BODY COMPOSITION; BODY MASS INDEX; CHILD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE; PRADER-WILLI SYNDROME; TREATMENT OUTCOME;

EID: 84873627657     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2881     Document Type: Article

References (45)

1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10-26.
2. Butler MG. Prader-Willi Syndrome: obesity due to genomic imprinting. Curr Genomics. 2011;12:204-215.
3. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M; speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183-4197.
4. Diene G, Mimoun E, Feigerlova E, et al. Endocrine disorders in children with Prader-Willi syndrome-data from 142 children of the French database. Horm Res Paediatr. 2010;74:121-128.
5. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87:1581-1585.
6. Sipilä I, Sintonen H, Hietanen H, et al. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatr. 2010;99:1712-1718.
7. Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2008;69:443-451.
8. de Lind van Wijngaarden RF, Siemensma EP, Festen DA, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94:4205-4215.
9. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2010;95:1131-1136.
10. Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res. 2000;53:200-206.
11. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88:2206-2212.
12. Colmenares A, Pinto G, Taupin P, et al. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome. Horm Res Paediatr. 2011;75:123-130.
13. Lindgren AC, Lindberg A. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database). Horm Res. 2008;70:182-187.
14. Reus L, Zwarts M, van Vlimmeren LA, Willemsen MA, Otten BJ, Nijhuis-van der Sanden MW. Motor problems in Prader-Willi syndrome: a systematic review on body composition and neuromuscular functioning. Neurosci Biobehav Rev. 2011;35:956-969.
15. Theodoro MF, Talebizadeh Z, Butler MG. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity (Silver Spring). 2006;14:1685-1690.
16. Sode-Carlsen R, Farholt S, Rabben KF, et al. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study. Endocrine. 2012;41:191-199.
17. Hö ybye C. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. Acta Paediatr. 2007;96:410-413.
18. Mogul HR, Lee PD, Whitman BY, et al. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial. J Clin Endocrinol Metab. 2008;93: 1238-1245.
19. Gondoni LA, Vismara L, Marzullo P, Vettor R, Liuzzi A, Grugni G. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome. J Endocrinol Invest. 2008;31: 765-772.
20. Marzullo P, Marcassa C, Campini R, et al. Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab. 2007;92:1364-1371.
21. Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol (Oxf). 2012;77:86-93.
22. Bekx MT, Carrel AL, Shriver TC, Li Z, Allen DB. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi syndrome. J Pediatr. 2003;143:372-376.
23. Van Mil EA, Westerterp KR, Gerver WJ, et al. Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. AmJ Clin Nutr. 2000;71:752-756.
24. Goldstone AP, Brynes AE, Thomas EL, et al. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in womenwith Prader-Willi syndrome. AmJ Clin Nutr. 2002;75:468-475.
25. Butler MG, Theodoro MF, Bittel DC, Donnelly JE. Energy expenditure and physical activity in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet A. 2007;143:449-459.
26. Tauber M, Barbeau C, Jouret B, et al. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. Horm Res. 2000;53:279-287.
27. Partsch CJ, Lämmer C, Gillessen-Kaesbach G, Pankau R. Adult patients with Prader-Willi syndrome: clinical characteristics, life circumstances and growth hormone secretion. Growth Horm IGF Res. 2000;10(suppl B):S81-S85.
28. Grugni G, Marzullo P, Ragusa L, et al. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2006;65:492-499.
29. Coupaye M, Bouillot JL, Coussieu C, Guy-Grand B, Basdevant A, Oppert JM. One-year changes in energy expenditure and serum leptin following adjustable silicone gastric banding in obese women. Obes Surg. 2005;15:827-833.
30. Coupaye M, Bouillot JL, Poitou C, Schutz Y, Basdevant A, Oppert JM. Is lean body mass decreased after obesity treatment by adjustable gastric banding? Obes Surg. 2007;17:427-433.
31. Weir JB. New methods for calculing metabolic rate with special reference to protein metabolism. J Physiol. 1949;109:1-9.
32. American Diabetes Association guidelines. Standards of medical care in diabetes. Diabetes Care. 2007;30(suppl 1):S4 -S41.
33. Graham I, Atar D, Borch-Johnsen K, Boysen G, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14: (suppl.2):S1-S113.
34. Société de Pneumologie de Langue Française; Société Française d'Anesthésie Réanimation; Société Française de Cardiologie; Société Française deMédecine du Travail; Société Française d'ORL; Société de Physiologie; Société Française de Recherche et de Médecine du Sommeil. Recommendations for clinical practice. Obstructive sleep apnea hypopnea syndrome in adults. RevMalRespir. 2010;27:806-833.
35. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
36. Cassidy SB, Forsythe M, Heeger S, Nicholls RD, Schork N, Benn P, Schwartz S. Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy15. Am J Med Genet. 1997;11;68:433-440.
37. Dudley O, Muscatelli F. Clinical evidence of intrauterine disturbance in Prader-Willi syndrome, a genetically imprinted neurodevelopmental disorder. Early Hum Dev. 2007;8:471-478.
38. Whittington JE, Butler JV, Holland AJ. Changing rates of genetic subtypes of Prader-Willi syndrome in the UK. Eur J Hum Genet. 2007;15:127-130.
39. Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A. 2007;143A:1456-1461.
40. Tauber M. 2007 Effect of growth hormone treatment in children presenting with Prader Willi syndrome: the KIGS experience. In: Ranke MB, Price DA, Reiter EO, eds. Growth hormone therapy in pediatrics-20 years of KIGS. Basel: Karger; 377-388
41. Goldstone AP, Thomas EL, Brynes AE, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab. 2001;86:4330-4338.
42. Sode-Carlsen R, Farholt S, Rabben KF, et al. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Horm IGF Res. 2010;20:179-184.
43. Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248-255.
44. Bray GA. Obesity increases risk for diabetes. Int J Obes Relat Metab Disord. 1992;16(suppl. 4):S13-S17.
45. Schmidt F, Kapellen TM, Wiegand S, et al. Diabetes mellitus in children and adolescents with genetic syndromes. Exp Clin Endocrinol Diabetes. 2012;120:579-585.